Isolated fully human monoclonal human anti-RANTES antibody or fragment thereof, wherein said antibody comprises: a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 8； a CDR2 region of VH comprising the amino acid sequence of SEQ ID NO: 9； a CDR3 region of VH comprising the amino acid sequence of SEQ ID NO: 20； a CDR1 region of VL comprising the amino acid sequence of SEQ ID NO: 14； a CDR2 region of VL comprising the amino acid sequence of SEQ ID NO: 15； and a CDR3 region of VL comprising an amino acid sequence of SEQ ID NO: 16, or b) a CDR1 region of VH comprising the amino acid sequence of SEQ ID NO: 8； a CDR2 region of VH comprising the amino acid sequence of SEQ ID NO: 9, a CDR3 region of VH comprising the amino acid sequence of SEQ ID NO: 10； a CDR1 region of VL comprising the amino acid sequence of SEQ ID NO: 14； a CDR2 region of VL comprising the amino acid sequence of SEQ ID NO: 15； and a CDR3 region of VL comprising an amino acid sequence of SEQ ID NO: 16 or c) a CDR1 region of VH comprising the amino acid sequence of SEQ ID NO: 28； a CDR2 region of VH comprising the amino acid sequence of SEQ ID NO: 29； a CDR3 region of VH comprising the amino acid sequence of SEQ ID NO: 30, a CDR1 region of VL comprising the amino acid sequence of SEQ ID NO: 34； a CDR2 region of VL comprising the amino acid sequence of SEQ ID NO: 35； and a CDR3 region of VL comprising an amino acid sequence of SEQ ID NO: 36； wherein said antibody binds to RANTES.Anticuerpo anti-RANTES humana monoclonal completamente humano aislado o fragmento del mismo, en el que dicho anticuerpo comprende: a) una región CDR1 de VH que comprende la secuencia de aminoácidos de SEQ ID NO: 8； una región CDR2 de VH que comprende la secuencia de aminoácidos de SEQ ID NO: 9； una región CDR3 de VH que comprende la secuencia de aminoácidos de SEQ ID NO: 20； una región CDR1 de VL que comprende la secuencia de aminoácidos de SEQ ID NO: 14； una región CDR2 de VL que comprende la secuencia de aminoác
